{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:23:44Z","timestamp":1791897824812,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although nivolumab (anti-programmed cell death-1 antibody) is a promising approach for advanced gastric cancer (AGC), the response rate remains limited. The aim of this multicenter retrospective study was to determine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty-eight patients with AGC who were treated with nivolumab as a third or later line from October 2017 to December 2018 at any of five clinical sites were enrolled in the study. The correlation between the best overall response and clinical features was investigated. Overall survival and progression-free survival after initiation of nivolumab were calculated and clinical features that could be predictors of the prognosis were sought.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The disease control rate (DCR) for nivolumab was 36.2% and was significantly correlated with performance status (<jats:italic>p<\/jats:italic>\u2009=\u20090.021), metastasis to one organ (<jats:italic>p<\/jats:italic>\u2009=\u20090.006), and grade 2 or higher immune-related adverse events (<jats:italic>p<\/jats:italic>\u2009=\u20090.027). There was also a significant association between response to nivolumab and ability to receive subsequent chemotherapy (<jats:italic>p<\/jats:italic>\u2009=\u20090.022). In the analysis of overall survival, the following variables were identified as being significantly associated with a poor outcome: Eastern Cooperative Oncology Group performance status \u22651, prior treatment with trastuzumab, no immune-related adverse events, lack of a response to nivolumab, and inability to receive subsequent chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings of this study suggest that nivolumab may be ineffective for AGC in patients with poor performance status and those with a history of treatment with trastuzumab.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09118-3","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T09:05:28Z","timestamp":1641200728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-5157","authenticated-orcid":false,"given":"Akihiko","family":"Sano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Ubukata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kuriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiharu","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Kogure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroomi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shirabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"9118_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer Association","year":"2018","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines. Gastric Cancer. 2018;24:1\u201321 5th ed.","journal-title":"Gastric Cancer"},{"key":"9118_CR2","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10:1063\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(09)70259-1.","journal-title":"Lancet Oncol"},{"key":"9118_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncol"},{"key":"9118_CR4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1093\/annonc\/mdn717","volume":"20","author":"YK Kang","year":"2009","unstructured":"Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20:666\u201373. https:\/\/doi.org\/10.1093\/annonc\/mdn717.","journal-title":"Ann Oncol"},{"key":"9118_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u201342. https:\/\/doi.org\/10.1200\/JCO.2007.13.9378.","journal-title":"J Clin Oncol"},{"key":"9118_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdu472.","journal-title":"Ann Oncol"},{"key":"9118_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"9118_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6.","journal-title":"Lancet Oncol"},{"key":"9118_CR9","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"9118_CR10","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","volume":"24","author":"N Boku","year":"2021","unstructured":"Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021;24:946\u201358. https:\/\/doi.org\/10.1007\/s10120-021-01173-w.","journal-title":"Gastric Cancer"},{"key":"9118_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer.1 version. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"9118_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8.","journal-title":"Lancet Oncol"},{"key":"9118_CR13","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12:1798\u2013805. https:\/\/doi.org\/10.1016\/j.jtho.2017.08.022.","journal-title":"J Thorac Oncol"},{"key":"9118_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"key":"9118_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant"},{"key":"9118_CR16","doi-asserted-by":"publisher","first-page":"e0247645","DOI":"10.1371\/journal.pone.0247645","volume":"16","author":"N Tokuyama","year":"2021","unstructured":"Tokuyama N, Takegawa N, Nishikawa M, Sakai A, Mimura T, Kushida S, et al. Pretreatment Glasgow prognostic score as a predictor of outcomes in nivolumab-treated patients with advanced gastric cancer. PLoS One. 2021;16:e0247645. https:\/\/doi.org\/10.1371\/journal.pone.0247645.","journal-title":"PLoS One"},{"key":"9118_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-020-07176-7","volume":"20","author":"T Matsumoto","year":"2020","unstructured":"Matsumoto T, Yamamoto Y, Kuriona Y, Okazaki U, Kimura S, Miura K, et al. Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses. BMC Cancer. 2020;20:684. https:\/\/doi.org\/10.1186\/s12885-020-07176-7.","journal-title":"BMC Cancer"},{"key":"9118_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41416-020-0975-7","volume":"123","author":"T Hagi","year":"2020","unstructured":"Hagi T, Kurokawa Y, Kawabata R, Omori T, Matsuyama J, Fujitani K, et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. 2020;123:965\u201372. https:\/\/doi.org\/10.1038\/s41416-020-0975-7.","journal-title":"Br J Cancer"},{"key":"9118_CR19","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s00595-020-02048-w","volume":"50","author":"T Namikawa","year":"2020","unstructured":"Namikawa T, Yokota K, Tanioka N, Fukudome I, Iwabu J, Munekage M, et al. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 2020;50:1486\u201395. https:\/\/doi.org\/10.1007\/s00595-020-02048-w.","journal-title":"Surg Today"},{"key":"9118_CR20","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2147\/OTT.S229813","volume":"13","author":"A Petrillo","year":"2020","unstructured":"Petrillo A, Tirino G, Zito Marino F, Pompella L, Sabetta R, Panarese I, et al. Nivolumab in heavily pretreated metastatic gastric Cancer patients: real-life data from a Western population. Onco Targets Ther. 2020;13:867\u201376. https:\/\/doi.org\/10.2147\/OTT.S229813.","journal-title":"Onco Targets Ther"},{"key":"9118_CR21","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7:24. https:\/\/doi.org\/10.1186\/s40425-019-0514-3.","journal-title":"J Immunother Cancer"},{"key":"9118_CR22","doi-asserted-by":"publisher","first-page":"34520","DOI":"10.18632\/oncotarget.26145","volume":"9","author":"T Ogata","year":"2018","unstructured":"Ogata T, Satake H, Ogata M, Hatachi Y, Inoue K, Hamada M, et al. Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget. 2018;9:34520\u20137. https:\/\/doi.org\/10.18632\/oncotarget.26145.","journal-title":"Oncotarget"},{"key":"9118_CR23","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10147-020-01833-4","volume":"26","author":"M Kano","year":"2021","unstructured":"Kano M, Hihara J, Tokumoto N, Kohashi T, Hara T, Shimbara K, et al. Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients. Int J Clin Oncol. 2021;26:523\u201331. https:\/\/doi.org\/10.1007\/s10147-020-01833-4.","journal-title":"Int J Clin Oncol"},{"key":"9118_CR24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","volume":"19","author":"K Masuda","year":"2019","unstructured":"Masuda K, Shoji H, Nagashima K, Yamamoto S, Ishikawa M, Imazeki H, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974. https:\/\/doi.org\/10.1186\/s12885-019-6150-y.","journal-title":"BMC Cancer"},{"key":"9118_CR25","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"key":"9118_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastrooesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(18)31257-1.","journal-title":"Lancet"},{"issue":"9","key":"9118_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1159\/000507219","volume":"98","author":"T Arigami","year":"2020","unstructured":"Arigami T, Matsushita D, Okubo K, Yanagita S, Ehi K, Sasaki K, et al. Response rate and prognostic impact of salvage chemotherapy after Nivolumab in patients with advanced gastric Cancer. Oncology. 2020;98(9):630\u20136. https:\/\/doi.org\/10.1159\/000507219.","journal-title":"Oncology."},{"key":"9118_CR28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 2018;4:374\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2925.","journal-title":"JAMA Oncol"},{"key":"9118_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1634\/theoncologist.2017-0384","volume":"23","author":"Y Toi","year":"2018","unstructured":"Toi Y, Sugawara S, Kawashima Y, Aiba T, Kawana S, Saito R, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist. 2018;23:1358\u201365. https:\/\/doi.org\/10.1634\/theoncologist.2017-0384.","journal-title":"Oncologist"},{"key":"9118_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00432-018-2805-3","volume":"145","author":"B Ricciuti","year":"2019","unstructured":"Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol. 2019;145:479\u201385. https:\/\/doi.org\/10.1007\/s00432-018-2805-3.","journal-title":"J Cancer Res Clin Oncol"},{"key":"9118_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10120-019-00970-8","volume":"23","author":"T Satoh","year":"2020","unstructured":"Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, et al. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric\/gastroesophageal junction cancer. Gastric Cancer. 2020;23:143\u201353. https:\/\/doi.org\/10.1007\/s10120-019-00970-8.","journal-title":"Gastric Cancer"},{"key":"9118_CR32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117\u201327. https:\/\/doi.org\/10.1016\/j.ccr.2004.06.022.","journal-title":"Cancer Cell"},{"key":"9118_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy. Cancer Discov. 2016;6:202\u201316. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0283.","journal-title":"Cancer Discov"},{"key":"9118_CR34","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.jocn.2010.04.021","volume":"17","author":"JS Waldron","year":"2010","unstructured":"Waldron JS, Yang I, Han S, Tihan T, Sughrue ME, Mills SA, et al. Implications for immunotherapy of tumor-mediated T-cell apoptosis associated with loss of the tumor suppressor PTEN in glioblastoma. J Clin Neurosci. 2010;17:1543\u20137. https:\/\/doi.org\/10.1016\/j.jocn.2010.04.021.","journal-title":"J Clin Neurosci"},{"key":"9118_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"9118_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3390\/cancers13040805","volume":"13","author":"H Kawakami","year":"2021","unstructured":"Kawakami H, Hironaka S, Esaki T, Chayama K, Tsuda M, Sugimoto N, et al. An investigator-initiated phase 2 study of nivolumab plus low-dose ipilimumab as first-line therapy for microsatellite instability-high advanced gastric or esophagogastric junction cancer (NO LIMIT, WJOG13320G\/CA209-7W7). Cancers (Basel). 2021;13:805. https:\/\/doi.org\/10.3390\/cancers13040805.","journal-title":"Cancers (Basel)"},{"key":"9118_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1078-0432.CCR-20-3559","volume":"27","author":"TE Nakajima","year":"2021","unstructured":"Nakajima TE, Kadowaki S, Minashi K, Nishina T, Yamanaka T, Hayashi Y, et al. Multicenter phase I\/II study of nivolumab combined with paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer. Clin Cancer Res. 2021;27:1029\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3559.","journal-title":"Clin Cancer Res"},{"key":"9118_CR38","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09118-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09118-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T09:11:37Z","timestamp":1641201097000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09118-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9118"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09118-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"assertion":[{"value":"10 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our study was carried out according to the relevant guidelines and regulations of the institutional and\/or national research committee and the 1964 Helsinki declaration. The study protocol was approved by the Institutional Review Board (IRB) of Gunma University Hospital (approval number HS2018\u2013237), Gunma Prefectural Cancer Center, National Hospital Organization Takasaki General Medical Center, Isesaki Municipal Hospital, and Japan Community Healthcare Organization Gunma Central Hospital. Because this study was strictly retrospective and involving the collection of existing data and records, the requirement to obtain informed consent was waived by the IRB of the Gunma University Hospital. And the opt-out method was used to obtain participant\u2019s consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}